Entrada Therapeutics, Inc. (TRDA) 10-Year Financial Performance & Capital Metrics

TRDA • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

AboutEntrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.Show more

Revenue $211M +63.4%
EBITDA $51M +15920.6%
Net Income $66M +1081.7%
EPS (Diluted) 1.68 +940.0%
Gross Margin 100%
EBITDA Margin 24.09% +9783.7%
Operating Margin 22.3% +1010.0%
Net Margin 31.13% +700.9%
ROE 19.56% +765.5%
ROIC 11.2% +1130.3%
Debt/Equity 0.14 -50.9%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 86 (top 14%)
✓Healthy 5Y average net margin of 13.0%
✓Trading at only 1.0x book value

✗Weaknesses

✗Negative free cash flow
✗Shares diluted 18.0% in last year

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-71.42%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-288.27%

EPS CAGR

10Y-

5Y-

3Y-

TTM-256.84%

ROCE

10Y Avg-37.19%

5Y Avg-30.14%

3Y Avg-8.71%

Latest11.79%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	129.01M	210.78M
Revenue Growth %	-	-	-	-	-	0.63%
Cost of Goods Sold+	104K	326K	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-
Gross Profit+	-104K	-326K	0	0	129.01M	210.78M
Gross Margin %	-	-	-	-	1%	1%
Gross Profit Growth %	-	-2.13%	1%	-	-	0.63%
Operating Expenses+	11.82M	26.34M	51.13M	97.25M	132.18M	163.77M
OpEx % of Revenue	-	-	-	-	1.02%	0.78%
Selling, General & Admin	3.61M	5.24M	15.2M	30.64M	32.29M	38.47M
SG&A % of Revenue	-	-	-	-	0.25%	0.18%
Research & Development	8.22M	21.1M	35.93M	66.61M	99.88M	125.31M
R&D % of Revenue	-	-	-	-	0.77%	0.59%
Other Operating Expenses	0	0	0	0	0	0
Operating Income+	-11.82M	-26.67M	-51.13M	-97.25M	-3.16M	47.01M
Operating Margin %	-	-	-	-	-0.02%	0.22%
Operating Income Growth %	-	-1.26%	-0.92%	-0.9%	0.97%	15.87%
EBITDA+	-11.72M	-26.34M	-50.01M	-95.35M	-321K	50.78M
EBITDA Margin %	-	-	-	-	-0%	0.24%
EBITDA Growth %	-	-1.25%	-0.9%	-0.91%	1%	159.21%
D&A (Non-Cash Add-back)	104K	326K	1.12M	1.9M	2.84M	3.77M
EBIT	-11.82M	-26.52M	-51.13M	-97.25M	-3.16M	47.01M
Net Interest Income+	0	0	0	0	15.22M	19.47M
Interest Income	0	0	0	2.63M	15.22M	19.47M
Interest Expense	0	0	0	2.63M	0	0
Other Income/Expense	6.72M	144K	-31K	2.63M	15.22M	19.47M
Pretax Income+	-5.1M	-26.52M	-51.16M	-94.62M	12.06M	66.48M
Pretax Margin %	-	-	-	-	0.09%	0.32%
Income Tax+	0	0	0	0	18.74M	859K
Effective Tax Rate %	0.91%	1%	1%	1%	-0.55%	0.99%
Net Income+	-4.65M	-26.52M	-51.16M	-94.62M	-6.68M	65.63M
Net Margin %	-	-	-	-	-0.05%	0.31%
Net Income Growth %	-	-4.71%	-0.93%	-0.85%	0.93%	10.82%
Net Income (Continuing)	-5.1M	-26.52M	-51.16M	-94.62M	-6.68M	65.63M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-4.44	-0.84	-1.60	-2.79	-0.20	1.68
EPS Growth %	-	0.81%	-0.9%	-0.74%	0.93%	9.4%
EPS (Basic)	-4.44	-0.84	-1.60	-2.79	-0.20	1.76
Diluted Shares Outstanding	1.05M	31.25M	31.22M	31.29M	33.05M	39M
Basic Shares Outstanding	1.05M	31.25M	31.22M	31.29M	33.05M	37.31M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	17.44M	39.95M	298.7M	209.88M	369.77M	440.04M
Cash & Short-Term Investments	16.84M	39.05M	291.06M	188.71M	351.97M	420M
Cash Only	16.84M	39.05M	291.06M	45.16M	67.6M	101.21M
Short-Term Investments	0	0	0	143.56M	284.37M	318.79M
Accounts Receivable	0	0	0	0	5.88M	3.68M
Days Sales Outstanding	-	-	-	-	16.63	6.37
Inventory	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	0	0	0	21.16M	11.92M	16.36M
Total Non-Current Assets+	801K	3.58M	7.13M	42.18M	99.42M	86.28M
Property, Plant & Equipment	801K	3.04M	6.26M	33.02M	92.68M	82.05M
Fixed Asset Turnover	-	-	-	-	1.39x	2.57x
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0
Other Non-Current Assets	0	541K	872K	9.16M	6.74M	4.23M
Total Assets+	18.24M	43.53M	305.83M	252.06M	469.19M	526.32M
Asset Turnover	-	-	-	-	0.27x	0.40x
Asset Growth %	-	1.39%	6.03%	-0.18%	0.86%	0.12%
Total Current Liabilities+	1.92M	3.36M	6.72M	21.97M	158.8M	39.48M
Accounts Payable	710K	1.6M	706K	5.99M	3.28M	4.26M
Days Payables Outstanding	2.49K	1.79K	-	-	-	-
Short-Term Debt	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	1000K	1000K
Other Current Liabilities	937K	1.6M	4.56M	5.49M	7.66M	8.43M
Current Ratio	9.08x	11.89x	44.46x	9.55x	2.33x	11.15x
Quick Ratio	9.08x	11.89x	44.46x	9.55x	2.33x	11.15x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	31.84M	81.66M	396K	17.53M	68.04M	58.16M
Long-Term Debt	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	17.53M	60.32M	51.65M
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	31.84M	81.66M	396K	0	0	0
Total Liabilities	33.76M	85.02M	7.12M	39.5M	226.83M	97.64M
Total Debt+	0	0	0	25.94M	68.23M	59.21M
Net Debt	-16.84M	-39.05M	-291.06M	-19.22M	628K	-42M
Debt / Equity	-	-	-	0.12x	0.28x	0.14x
Debt / EBITDA	-	-	-	-	-	1.17x
Net Debt / EBITDA	-	-	-	-	-	-0.83x
Interest Coverage	-	-	-	-36.95x	-	-
Total Equity+	-15.52M	-41.49M	298.72M	212.55M	242.36M	428.68M
Equity Growth %	-	-1.67%	8.2%	-0.29%	0.14%	0.77%
Book Value per Share	-14.81	-1.33	9.57	6.79	7.33	10.99
Total Shareholders' Equity	-15.52M	-41.49M	298.72M	212.55M	242.36M	428.68M
Common Stock	0	0	3K	3K	3K	4K
Retained Earnings	-15.99M	-42.51M	-93.67M	-188.28M	-194.97M	-129.34M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	0	0	0	-2.06M	195K	-43K
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-10.8M	-25.57M	-50.86M	-93.79M	139.8M	-41.56M
Operating CF Margin %	-	-	-	-	1.08%	-0.2%
Operating CF Growth %	-	-1.37%	-0.99%	-0.84%	2.49%	-1.3%
Net Income	-5.1M	-26.52M	-51.16M	-94.62M	-6.68M	65.63M
Depreciation & Amortization	104K	326K	1.12M	1.9M	2.84M	3.77M
Stock-Based Compensation	0	325K	2.53M	0	13.11M	17.91M
Deferred Taxes	0	0	0	0	0	0
Other Non-Cash Items	-5.98M	20K	74K	10.05M	-5.78M	-10.02M
Working Capital Changes	174K	282K	-3.42M	-11.11M	136.31M	-118.85M
Change in Receivables	0	0	0	0	0	2.2M
Change in Inventory	0	0	0	0	0	0
Change in Payables	367K	631K	-715K	5.29M	-2.81M	991K
Cash from Investing+	-630K	-2.32M	-4.58M	-148.65M	-138.4M	-27.8M
Capital Expenditures	-630K	-2.32M	-4.58M	-2.89M	-5.61M	-3.16M
CapEx % of Revenue	-	-	-	-	0.04%	0.01%
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0
Cash from Financing+	38K	50.09M	307.46M	479K	21.04M	102.96M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	0	247K	939K	0	1.63M	3.36M
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-11.43M	-27.89M	-55.44M	-96.67M	134.19M	-44.72M
FCF Margin %	-	-	-	-	1.04%	-0.21%
FCF Growth %	-	-1.44%	-0.99%	-0.74%	2.39%	-1.33%
FCF per Share	-10.91	-0.89	-1.78	-3.09	4.06	-1.15
FCF Conversion (FCF/Net Income)	2.32x	0.96x	0.99x	0.99x	-20.91x	-0.63x
Interest Paid	0	0	0	0	0	0
Taxes Paid	0	0	0	0	14.72M	4.62M

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-39.78%	-37.01%	-2.94%	19.56%
Return on Invested Capital (ROIC)	-	-	-	-72.58%	-1.09%	11.2%
Gross Margin	-	-	-	-	100%	100%
Net Margin	-	-	-	-	-5.18%	31.13%
Debt / Equity	-	-	-	0.12x	0.28x	0.14x
Interest Coverage	-	-	-	-36.95x	-	-
FCF Conversion	2.32x	0.96x	0.99x	0.99x	-20.91x	-0.63x
Revenue Growth	-	-	-	-	-	63.38%

Revenue by Segment

	2023	2024
License	139M	20.2M
License Growth	-	-85.47%

Frequently Asked Questions

Valuation & Price

Entrada Therapeutics, Inc. (TRDA) has a price-to-earnings (P/E) ratio of 6.4x. This may indicate the stock is undervalued or faces growth challenges.

Growth & Financials

Entrada Therapeutics, Inc. (TRDA) reported $61.5M in revenue for fiscal year 2024.

Entrada Therapeutics, Inc. (TRDA) grew revenue by 63.4% over the past year. This is strong growth.

Entrada Therapeutics, Inc. (TRDA) reported a net loss of $103.5M for fiscal year 2024.

Dividend & Returns

Entrada Therapeutics, Inc. (TRDA) has a return on equity (ROE) of 19.6%. This is reasonable for most industries.

Entrada Therapeutics, Inc. (TRDA) had negative free cash flow of $129.8M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener